239 related articles for article (PubMed ID: 19759354)
1. Quantification of Gi-mediated inhibition of adenylyl cyclase activity reveals that UDP is a potent agonist of the human P2Y14 receptor.
Carter RL; Fricks IP; Barrett MO; Burianek LE; Zhou Y; Ko H; Das A; Jacobson KA; Lazarowski ER; Harden TK
Mol Pharmacol; 2009 Dec; 76(6):1341-8. PubMed ID: 19759354
[TBL] [Abstract][Full Text] [Related]
2. Gi-dependent cell signaling responses of the human P2Y14 receptor in model cell systems.
Fricks IP; Carter RL; Lazarowski ER; Harden TK
J Pharmacol Exp Ther; 2009 Jul; 330(1):162-8. PubMed ID: 19339661
[TBL] [Abstract][Full Text] [Related]
3. A selective high-affinity antagonist of the P2Y14 receptor inhibits UDP-glucose-stimulated chemotaxis of human neutrophils.
Barrett MO; Sesma JI; Ball CB; Jayasekara PS; Jacobson KA; Lazarowski ER; Harden TK
Mol Pharmacol; 2013 Jul; 84(1):41-9. PubMed ID: 23592514
[TBL] [Abstract][Full Text] [Related]
4. UDP-sugars activate P2Y
Abbas ZSB; Latif ML; Dovlatova N; Fox SC; Heptinstall S; Dunn WR; Ralevic V
Vascul Pharmacol; 2018 Apr; 103-105():36-46. PubMed ID: 29253618
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological effects mediated by UDP-glucose that are independent of P2Y14 receptor expression.
Scrivens M; Dickenson JM
Pharmacol Res; 2005 Jun; 51(6):533-8. PubMed ID: 15829433
[TBL] [Abstract][Full Text] [Related]
6. Is GPR17 a P2Y/leukotriene receptor? examination of uracil nucleotides, nucleotide sugars, and cysteinyl leukotrienes as agonists of GPR17.
Qi AD; Harden TK; Nicholas RA
J Pharmacol Exp Ther; 2013 Oct; 347(1):38-46. PubMed ID: 23908386
[TBL] [Abstract][Full Text] [Related]
7. Functional expression of the P2Y14 receptor in human neutrophils.
Scrivens M; Dickenson JM
Eur J Pharmacol; 2006 Aug; 543(1-3):166-73. PubMed ID: 16820147
[TBL] [Abstract][Full Text] [Related]
8. Role of UDP-Sugar Receptor P2Y
Mikolajewicz N; Komarova SV
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32326617
[TBL] [Abstract][Full Text] [Related]
9. UDP is a competitive antagonist at the human P2Y14 receptor.
Fricks IP; Maddileti S; Carter RL; Lazarowski ER; Nicholas RA; Jacobson KA; Harden TK
J Pharmacol Exp Ther; 2008 May; 325(2):588-94. PubMed ID: 18252808
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel P2Y14 agonist and antagonist using conventional and nonconventional methods.
Hamel M; Henault M; Hyjazie H; Morin N; Bayly C; Skorey K; Therien AG; Mancini J; Brideau C; Kargman S
J Biomol Screen; 2011 Oct; 16(9):1098-105. PubMed ID: 21821827
[TBL] [Abstract][Full Text] [Related]
11. Identification of a carbohydrate recognition motif of purinergic receptors.
Zhao L; Wei F; He X; Dai A; Yang D; Jiang H; Wen L; Cheng X
Elife; 2023 Nov; 12():. PubMed ID: 37955640
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationship of uridine 5'-diphosphoglucose analogues as agonists of the human P2Y14 receptor.
Ko H; Fricks I; Ivanov AA; Harden TK; Jacobson KA
J Med Chem; 2007 May; 50(9):2030-9. PubMed ID: 17407275
[TBL] [Abstract][Full Text] [Related]
13. Evidence for receptor-regulated phosphotransfer reactions involved in activation of the adenylate cyclase inhibitory G protein in human platelet membranes.
Jakobs KH; Wieland T
Eur J Biochem; 1989 Jul; 183(1):115-21. PubMed ID: 2502397
[TBL] [Abstract][Full Text] [Related]
14. Human immature monocyte-derived dendritic cells express the G protein-coupled receptor GPR105 (KIAA0001, P2Y14) and increase intracellular calcium in response to its agonist, uridine diphosphoglucose.
Skelton L; Cooper M; Murphy M; Platt A
J Immunol; 2003 Aug; 171(4):1941-9. PubMed ID: 12902497
[TBL] [Abstract][Full Text] [Related]
15. Uridine nucleotide selectivity of three phospholipase C-activating P2 receptors: identification of a UDP-selective, a UTP-selective, and an ATP- and UTP-specific receptor.
Nicholas RA; Watt WC; Lazarowski ER; Li Q; Harden K
Mol Pharmacol; 1996 Aug; 50(2):224-9. PubMed ID: 8700127
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological and second messenger signalling selectivities of cloned P2Y receptors.
Nicholas RA; Lazarowski ER; Watt WC; Li Q; Boyer J; Harden TK
J Auton Pharmacol; 1996 Dec; 16(6):319-23. PubMed ID: 9131407
[TBL] [Abstract][Full Text] [Related]
17. UDP-glucose acting at P2Y14 receptors is a mediator of mast cell degranulation.
Gao ZG; Ding Y; Jacobson KA
Biochem Pharmacol; 2010 Mar; 79(6):873-9. PubMed ID: 19896471
[TBL] [Abstract][Full Text] [Related]
18. Thrombin-promoted release of UDP-glucose from human astrocytoma cells.
Kreda SM; Seminario-Vidal L; Heusden Cv; Lazarowski ER
Br J Pharmacol; 2008 Apr; 153(7):1528-37. PubMed ID: 18204471
[TBL] [Abstract][Full Text] [Related]
19. Geniposide attenuates inflammatory response by suppressing P2Y14 receptor and downstream ERK1/2 signaling pathway in oxygen and glucose deprivation-induced brain microvascular endothelial cells.
Li F; Li W; Li X; Li F; Zhang L; Wang B; Huang G; Guo X; Wan L; Liu Y; Zhang S; Kang S; Ma J
J Ethnopharmacol; 2016 Jun; 185():77-86. PubMed ID: 26976766
[TBL] [Abstract][Full Text] [Related]
20. The purinergic P2Y14 receptor links hepatocyte death to hepatic stellate cell activation and fibrogenesis in the liver.
Mederacke I; Filliol A; Affo S; Nair A; Hernandez C; Sun Q; Hamberger F; Brundu F; Chen Y; Ravichandra A; Huebener P; Anke H; Shi H; Martínez García de la Torre RA; Smith JR; Henderson NC; Vondran FWR; Rothlin CV; Baehre H; Tabas I; Sancho-Bru P; Schwabe RF
Sci Transl Med; 2022 Apr; 14(639):eabe5795. PubMed ID: 35385339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
